Maze Therapeutics' Lead Drug Shows Promise in Kidney Disease Trial

TL;DR

**MAZE's MZE829 just hit a key clinical milestone for AMKD, making it a speculative buy for those betting on precision medicine in kidney disease.**

AI Summary

Maze Therapeutics, Inc. (MAZE) is a clinical-stage biopharmaceutical company focused on kidney and metabolic diseases. For the fiscal year ended December 31, 2025, the company reported positive topline clinical proof of concept data in March 2026 for its lead program, MZE829, an APOL1 inhibitor for APOL1-mediated kidney disease (AMKD). The Phase 2 trial showed a mean reduction in urinary albumin-to-creatinine ratio (uACR) of 35.6% at week 12 in evaluable AMKD patients, with a 61.8% reduction in FSGS patients. MZE782, for phenylketonuria (PKU) and chronic kidney disease (CKD), completed a Phase 1 trial in September 2025, demonstrating target engagement and a favorable pharmacokinetic profile. The company plans to initiate two Phase 2 trials for MZE782 in 2026. Maze Therapeutics has incurred significant operating losses since inception and expects continued losses, requiring substantial additional capital to finance operations and achieve goals. The aggregate market value of common stock held by non-affiliates was approximately $443.9 million as of June 30, 2025, based on a closing price of $12.27 per share.

Why It Matters

Maze Therapeutics' positive Phase 2 data for MZE829 in AMKD, a genetically defined subset of CKD with no approved treatment, could significantly impact patients of West African ancestry who are disproportionately affected. For investors, this clinical validation de-risks a key pipeline asset, potentially increasing MAZE's valuation in a competitive biopharmaceutical landscape dominated by larger players like AstraZeneca and Novartis. Successful commercialization would establish MAZE as a leader in precision medicine for kidney diseases, attracting further investment and potentially spurring M&A activity. Employees benefit from the company's progress, securing jobs and potentially increasing equity value.

Risk Assessment

Risk Level: high — Maze Therapeutics is a clinical-stage biopharmaceutical company with a limited operating history and has not generated any product revenue, expecting continued significant operating losses for the foreseeable future. The company will require substantial additional capital to finance operations, and failure to raise capital could force delays or elimination of research programs. Its success is highly dependent on the commercialization of MZE829 and MZE782, both of which are still in early to mid-stage clinical development, facing lengthy and expensive processes with uncertain outcomes.

Analyst Insight

Investors should closely monitor the continued enrollment and future data readouts for MZE829's Phase 2 trial and the initiation of MZE782's Phase 2 trials in 2026. Given the high-risk, high-reward nature of clinical-stage biotech, consider a small, speculative position if you have a high-risk tolerance and believe in the long-term potential of their Compass platform and precision medicine approach.

Financial Highlights

debt To Equity

Not disclosed

revenue

Not disclosed

operating Margin

Not disclosed

total Assets

Not disclosed

total Debt

Not disclosed

net Income

Not disclosed

eps

Not disclosed

gross Margin

Not disclosed

cash Position

Not disclosed

revenue Growth

Not disclosed

Key Numbers

• $443.9 million — Aggregate market value of common stock held by non-affiliates (as of June 30, 2025, indicating current market capitalization for non-insiders)
• $12.27 — Closing price per share (on June 30, 2025, used to calculate market value)
• 35.6% — Mean reduction in uACR for MZE829 (at week 12 in evaluable AMKD patients in Phase 2 trial, indicating efficacy)
• 61.8% — Mean uACR reduction for MZE829 (in a subset of FSGS patients, highlighting strong efficacy in a specific AMKD subgroup)
• 111 — Healthy adult volunteers enrolled in MZE829 Phase 1 trial (demonstrating initial safety and pharmacokinetics)
• 15 — Patients enrolled in MZE829 Phase 2 trial (for safety and tolerability analysis)
• 12 — Patients evaluable for efficacy in MZE829 Phase 2 trial (providing the basis for the positive topline data)
• 112 — Healthy adult volunteers enrolled in MZE782 Phase 1 trial (demonstrating initial safety and pharmacokinetic profile)
• 49,708,658 — Shares of common stock outstanding (as of March 20, 2026)
• 2026 — Planned initiation of two Phase 2 trials for MZE782 (indicating upcoming clinical milestones)

Key Players & Entities

• Maze Therapeutics, Inc. (company) — registrant
• MZE829 (company) — lead therapeutic candidate
• MZE782 (company) — second therapeutic candidate
• APOL1-mediated kidney disease (regulator) — disease target for MZE829
• phenylketonuria (regulator) — disease target for MZE782
• chronic kidney disease (regulator) — disease target for MZE782
• Shionogi & Co., Ltd (company) — partner for MZE001
• Nasdaq Stock Market LLC (regulator) — exchange for common stock
• Securities and Exchange Commission (regulator) — filing oversight
• Compass platform (company) — proprietary drug discovery platform

Forward-Looking Statements

• Maze Therapeutics will continue to operate in the 'Biological Products' sector. (Maze Therapeutics, Inc.) — high confidence, target: 2027-12-31
• The company's next annual report (10-K) will cover the fiscal year ending December 31, 2026. (Maze Therapeutics, Inc.) — high confidence, target: 2027-03-31

FAQ

Risk Factors

• Need for substantial additional capital [high — financial]: Maze Therapeutics has incurred significant operating losses since inception and expects continued losses. The company requires substantial additional capital to finance its operations and achieve its goals, including the development and commercialization of its therapeutic candidates. Failure to secure sufficient funding could impede progress and impact the company's ability to continue as a going concern.
• Obtaining and maintaining regulatory approval [high — regulatory]: The company's ability to develop, obtain, and maintain regulatory approval for its therapeutic candidates, such as MZE829 and MZE782, is subject to significant uncertainties. The process involves extensive clinical trials, and there is no guarantee that these candidates will demonstrate sufficient safety and efficacy to gain approval from regulatory bodies like the FDA.
• Clinical trial success and timelines [high — operational]: The success of Maze Therapeutics' business is heavily dependent on the successful and timely completion of its clinical trials. Positive topline data for MZE829 in March 2026 was a key milestone, but future trials for MZE829 and MZE782 (planned to initiate in 2026) carry inherent risks of failure or delays. The company's ability to meet projected timelines for these trials is critical.
• Competition in kidney and metabolic diseases [medium — market]: The biopharmaceutical industry, particularly in the areas of kidney and metabolic diseases, is highly competitive. Maze Therapeutics faces competition from numerous companies, including large pharmaceutical companies and other biotechnology firms, that are developing therapies for similar indications. This competitive landscape could impact market penetration and pricing power.
• Reliance on key personnel [medium — operational]: The company's success depends on its ability to attract and retain highly qualified scientific, clinical, and management personnel. The loss of key individuals could disrupt research and development efforts and strategic planning.
• Burn rate and cash runway [high — financial]: As a clinical-stage company with significant operating losses, Maze Therapeutics has a high cash burn rate. The company's ability to manage its cash runway and secure future financing rounds is crucial for sustaining operations and advancing its pipeline.
• Adverse events and safety profiles [high — regulatory]: While MZE829 showed positive efficacy signals, the safety and tolerability of its therapeutic candidates in larger patient populations and over longer durations remain critical. Any unexpected adverse events could lead to trial halts, regulatory setbacks, or market rejection.
• Market adoption of novel therapies [medium — market]: Even if Maze Therapeutics' therapies gain regulatory approval, their successful commercialization depends on market adoption by physicians and patients. Factors such as physician prescribing habits, patient adherence, and reimbursement policies will influence the uptake of MZE829 and MZE782.

Industry Context

Maze Therapeutics operates in the highly competitive biopharmaceutical sector, focusing on the unmet needs in kidney and metabolic diseases. The industry is characterized by significant R&D investment, lengthy development cycles, and stringent regulatory oversight. Recent trends show increasing interest in genetically targeted therapies and precision medicine approaches, which aligns with Maze's strategy for AMKD and potentially PKU.

Regulatory Implications

The company faces significant regulatory hurdles in bringing its drug candidates to market. Successful navigation of FDA (and potentially other global regulatory bodies) requirements for MZE829 and MZE782 is paramount. Demonstrating robust safety and efficacy data in larger clinical trials will be critical for approval, and any delays or adverse findings could have severe financial and operational consequences.

What Investors Should Do

1. Monitor upcoming Phase 2 trial initiations for MZE782 in 2026.
2. Closely track future clinical trial results for MZE829, particularly in broader AMKD patient populations.
3. Assess the company's ability to secure additional funding.
4. Evaluate the competitive landscape for AMKD and PKU treatments.

Key Dates

• 2025-03-31: Positive topline clinical proof of concept data for MZE829 — Demonstrated efficacy of lead program MZE829 in AMKD patients, with a 35.6% mean reduction in uACR, boosting investor confidence.
• 2025-09-30: Completion of Phase 1 trial for MZE782 — Showcased target engagement and favorable pharmacokinetics for MZE782, paving the way for further development in PKU and CKD.
• 2025-06-30: Aggregate market value of common stock held by non-affiliates was $443.9 million — Indicates the company's market capitalization as perceived by public investors at that time.
• 2026-01-01: Planned initiation of two Phase 2 trials for MZE782 — Represents upcoming critical clinical development milestones for the MZE782 program.

Glossary

APOL1-mediated kidney disease (AMKD)

A type of kidney disease caused by specific genetic mutations in the APOL1 gene, which are more prevalent in individuals of African descent. (This is the primary indication for Maze Therapeutics' lead drug candidate, MZE829, highlighting the company's focus on a specific genetic driver of kidney disease.)

Urinary albumin-to-creatinine ratio (uACR)

A laboratory test used to measure the amount of albumin (a protein) in the urine relative to creatinine. It is a key indicator of kidney damage and disease progression. (The reduction in uACR is a primary efficacy endpoint for MZE829, and the reported 35.6% reduction is a key data point for assessing the drug's effectiveness.)

Phenylketonuria (PKU)

A rare inherited metabolic disorder that prevents the body from properly breaking down an amino acid called phenylalanine. (PKU is one of the indications for Maze Therapeutics' MZE782 program, indicating the company's expansion into metabolic diseases beyond kidney disorders.)

Chronic Kidney Disease (CKD)

A progressive condition where the kidneys gradually lose function over time. (CKD is another indication for MZE782, showing the drug's potential application in a broader range of kidney-related conditions.)

Target engagement

The extent to which a drug binds to and interacts with its intended biological target in the body. (Demonstrating target engagement in Phase 1 trials, as with MZE782, is crucial for validating the drug's mechanism of action and supporting further clinical development.)

Pharmacokinetic profile

Describes how a drug is absorbed, distributed, metabolized, and excreted by the body over time. (A favorable pharmacokinetic profile, observed in MZE782's Phase 1 trial, suggests the drug has suitable properties for effective dosing and therapeutic effect.)

Forward-looking statements

Statements made in company filings that predict or project future events or performance, often qualified with terms like 'expect,' 'believe,' or 'anticipate.' (These statements are subject to risks and uncertainties, and actual results may differ materially, as noted in the filing's special note.)

Aggregate market value of common stock held by non-affiliates

The total market value of a company's shares held by investors who are not company insiders (e.g., executives, directors). (This metric provides an indication of the company's public market capitalization, excluding shares held by those with inside knowledge.)

Year-Over-Year Comparison

This analysis is based on a single 10-K filing and does not contain comparative data from a previous filing. Therefore, a comparison of key metrics such as revenue growth, margin changes, or the emergence of new risks cannot be provided.

Key Financial Figures

• $0.001 — h registered Common Stock - par value $0.001 per share MAZE The Nasdaq Stock Mar
• $12.27 — q Stock Market LLC on June 30, 2025, of $12.27 per share. Shares of the registrant's c

Filing Documents

• maze-20251231.htm (10-K) — 3567KB
• maze-ex4_1.htm (EX-4.1) — 53KB
• maze-ex10_19.htm (EX-10.19) — 782KB
• maze-ex21_1.htm (EX-21.1) — 2KB
• maze-ex23_1.htm (EX-23.1) — 6KB
• maze-ex31_1.htm (EX-31.1) — 16KB
• maze-ex31_2.htm (EX-31.2) — 16KB
• maze-ex32_1.htm (EX-32.1) — 12KB
• maze-ex32_2.htm (EX-32.2) — 12KB
• img27926017_0.jpg (GRAPHIC) — 216KB
• img27926017_1.jpg (GRAPHIC) — 87KB
• img27926017_2.jpg (GRAPHIC) — 137KB
• 0001193125-26-122778.txt ( ) — 16311KB
• maze-20251231.xsd (EX-101.SCH) — 1842KB
• maze-20251231_htm.xml (XML) — 2679KB

Business

Business 4 Item 1A.

Risk Factors

Risk Factors 26 Item 1B. Unresolved Staff Comments 75 Item 1C. Cybersecurity 75 Item 2.

Properties

Properties 76 Item 3.

Legal Proceedings

Legal Proceedings 76 Item 4. Mine Safety Disclosures 76 PART II 77 Item 5. Market for Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities 77 Item 6. [Reserved] 77 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of

Management's Discussion and Analysis of Financial Condition and Results of Operations 78 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 90 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 91 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 121 Item 9A.

Controls and Procedures

Controls and Procedures 121 Item 9B. Other Information 122 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 122 PART III 123 Item 10. Directors, Executive Officers and Corporate Governance 123 Item 11.

Executive Compensation

Executive Compensation 123 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 123 Item 13. Certain Relationships and Related Transactions, and Director Independence 123 Item 14. Principal Accountant Fees and Services 123 PART IV 124 Item 15. Exhibits and Financial Statement Schedules 124 Item 16. Form 10-K Summary 126 SIGNATURE PAGE 127 Special note regarding forward-looking statements This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and the Private Securities Litigation Reform Act of 1995. These statements appear throughout this Annual Report on Form 10-K and are statements regarding our intent, belief, or current expectations, primarily with respect to our business and related industry developments. In some cases, you can identify forward-looking statements by terms such as "believe," "may," "will," "potentially," "estimate," "continue," "anticipate," "intend," "could," "would," "project," "plan," "expect" and similar expressions that convey uncertainty of future events or outcomes, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in "Risk Factors" and elsewhere in this Annual Report on Form 10-K. Moreover, we operate in a competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circum

Bu siness

Item 1. Bu siness Overview We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with kidney and metabolic diseases. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants associated with health and disease and then determine how these drive risk for and protection against disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly-owned clinical programs, MZE829 and MZE782. Our most advanced program, MZE829, is an oral, small molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1-mediated kidney disease, or AMKD, a genetically defined sub-set of chronic kidney disease, or CKD, for which there is no approved treatment today. In October 2024, we reported results from our Phase 1 clinical trial of MZE829, in which we enrolled 111 healthy adult volunteers. MZE829 was well tolerated and demonstrated dose-proportional pharmacokinetics, or PK. We initiated a Phase 2 trial of MZE829 in November 2024, dosed our first patient in February 2025 and reported positive topline clinical proof of concept data in March 2026. The open-label study enrolled 15 patients, all of whom were included in a safety and tolerability analysis, and 12 of whom were evaluable for efficacy. MZE829 was well tolerated, and treatment with MZE829 resulted in a mean reduction in urinary albumin-to-creatinine ratio, or uACR, of 35.6% at week 12 in evaluable patients with broad AMKD, with 50% of such patients achieving at least a 30% reduction in uACR. In a subset of patients with focal segmental glomerulosclerosis, or FSGS, mean uACR reduction was 61.8%. Treatment of non-diabetic AMKD

View Full Filing

View this 10-K filing on SEC EDGAR